| Name | Title | Contact Details |
|---|---|---|
Natalie Blanchard |
Director of HR | Profile |
MAS is at the forefront of Singapores rapidly growing financial industry, creating new policies and initiatives that address the ever-changing landscape. Work at MAS promises not only challenges worthy of your intellectual abilities, but also the personal satisfaction that comes from building one of Asias premier financial hubs. We invite you to take up the challenge and make a difference to Singapores economic and financial development! At MAS, we place a great emphasis on developing a vibrant and conducive work environment that motivates each and every employee to make a meaningful contribution to the organisation. Our people recognize the importance of upholding our values to achieve more together. We believe that it is essential that our people enjoy working here with one another. MAS Functions - To act as the central bank of Singapore, including the conduct of monetary policy, the issuance of currency, the oversight of payment systems and serving as banker to and financial agent of the Government - To conduct integrated supervision of financial services and financial stability surveillance - To manage the official foreign reserves of Singapore - To develop Singapore as an international financial centre
Modernizing and simplifying the landscape design and install process. Locally owned and operated in Woodbury, Minnesota. We are the catalyst for your outdoor dream space. OUR STORY Locally established here by 4 high school athletes in 2016. Passionate about making a positive impact in our community. Our expertise, quality, and reliability have helped us continue to grow and serve the residents and businesses of Eastside Twin Cities. Check out our website below for a full list of our services!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.